POTOMAC, Md., June 25, 2024--IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
POTOMAC, Md., June 24, 2024--IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
POTOMAC, Md., June 18, 2024--IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets